|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||78.03 - 79.04|
|52 Week Range||67.74 - 80.44|
|Beta (3Y Monthly)||0.36|
|PE Ratio (TTM)||22.20|
|Earnings Date||Jul 29, 2019|
|Forward Dividend & Yield||3.07 (3.94%)|
|1y Target Est||82.62|
Sanofi on Wednesday said a reorganisation of its research and development operation in Germany and France would result in 466 job cuts in the two countries. In an emailed statement, a spokesman with the French drugmaker said the reshuffle aimed at enabling Sanofi to concentrate its research efforts in cancer, immunology, rare diseases and vaccines. The 466 job cuts are to be implemented on a voluntary basis, Sanofi said.
Sanofi SA (NASDAQ: SNY ) and Alphabet Inc (NASDAQ: GOOG ) (NASDAQ: GOOGL ) said Tuesday they have joined forces to launch a virtual Innovation lab with the aim of transforming how medicine and health services ...
French healthcare company Sanofi has teamed up with Google to work on innovations, aimed at using emerging data technologies to change how medicines and health services will be delivered in future. Sanofi and Google will use data sets to improve their understanding of key diseases and extract patients' insights and feedback, the companies said in a joint statement. "Combining Sanofi's biologic innovations and scientific data with Google's industry-leading capabilities, from cloud computing to state-of-the-art artificial intelligence, we aspire to give people more control over their health and accelerate the discovery of new therapies," said Ameet Nathwani, chief medical officer and executive vice-president, Sanofi.
June 18, 2019 – Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. “We stand on the forefront of a new age for biology and human health, with the opportunity to transform healthcare through partnerships with pioneering technology and analytics companies,” says Ameet Nathwani, M.D., Chief Digital Officer, Chief Medical Officer & Executive Vice President, Medical at Sanofi.
(Bloomberg) -- Alphabet Inc.’s Google will bring its artificial-intelligence and cloud-computing capabilities to a new partnership with pharma giant Sanofi.The project is aimed at accelerating the discovery of new medicines, increasing the understanding of what treatments work for patients and making Sanofi’s operations more efficient, the Paris-based drugmaker said in a statement Tuesday. The companies didn’t provide financial details.The pact is the latest sign of increasing collaboration between the technology and health-care industries. Pharma companies like Sanofi are teaming up with AI specialists, hiring data scientists or even snapping up tech startups in a bid to become faster and more efficient as costs rise.The new partnership will allow Sanofi to come up with more personalized approaches to treatment, the company said. The drugmaker and Google also plan to apply artificial intelligence to forecast sales and improve marketing and supply efforts.To contact the reporter on this story: James Paton in London at email@example.comTo contact the editors responsible for this story: Eric Pfanner at firstname.lastname@example.org, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Healthcare was slow to benefit from digitalisation. Heavy regulations, pricing power and a history of failed IT projects were to blame. Tuesday’s tie-up between Google and French drugmaker Sanofi to create a “virtual innovation lab” is the latest example.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article.
Soliqua ® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments Patients switched to Soliqua reached an average blood sugar below the American Diabetes ...
With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth. Sanofi has a mandatory 65-year-old retirement age for its CEO.
Bringing in Paul Hudson as its next chief executive officer will help the French pharma giant bolster its pipeline of medicines and deal with growing U.S. pressure on drug prices. The 51-year-old British executive will take over in September from Olivier Brandicourt, 63, who’s retiring. Hudson has led Novartis’s pharma unit since 2016 and is credited with launching key medicines such as psoriasis treatment Cosentyx, which may become its top product this year with a projected $3.5 billion in sales.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...
* Hudson from Novartis to join Sanofi from Sept. 1 * Current CEO Brandicourt to retire * Shares up almost 5 percent (Adds share price, comment) By Matthias Blamont PARIS, June 7 (Reuters) - Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. Hudson, who is British, will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest move by a Novartis executive to a competitor.
European stocks were on course to notch their best weekly performance in two months on Friday as a jump in shares of French pharma giant Sanofi added to the positive mood created by expectations of more moves by central banks to stir growth. France's CAC 40 outperformed its peers with a 1.2% rise, helped by a 4.5% jump in Sanofi after the company appointed Swiss rival Novartis' executive Paul Hudson as its new boss.
French drugmaker Sanofi has announced that a top executive from Swiss rival Novartis will succeed Olivier Brandicourt as CEO. Paul Hudson, who was most recently chief executive of the Novartis pharmaceuticals business and member of the executive committee of the overall group, will take over on September 1. since Sanofi’s diabetes treatments lost patent protection and came under pressure from cheaper rivals.
European stocks were in recovery mode on Friday after a cautious message from the European Central Bank hit investors' appetite for risk in the previous session, with traders eyeing a U.S. jobs report and U.S. trade tussles with Mexico for fresh direction. Automakers climbed on a report that U.S. President Donald Trump could delay the tariffs he had threatened to put on Mexican goods as soon as this coming Monday, while French drugmaker Sanofi gained on its appointment of a new chief executive. France's CAC 40 outperformed its euro-peers with a 0.9%, helped by French pharma giant Sanofi.
Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday. Hudson will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest transfer of a Novartis executive to a competitor. UK-born Hudson, 51, has been CEO of the Novartis Pharmaceuticals, one of the Swiss company's three main divisions, since 2016.
June 7, 2019 - At its meeting on June 6th of 2019, Sanofi`s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire. The Board of Directors would like to thank Olivier Brandicourt for the energy with which he has steered the Group through a complex period and for his decisive contribution to the company`s return to growth.
Germany's highest civil court on Tuesday rejected French drugmaker Sanofi's bid to fend off a legal challenge by U.S. rival Amgen against Sanofi's cholesterol drug Praluent. In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special licence that would have protected its Praluent business. Officials at Sanofi did not have an immediate comment.
The list of drugmakers to be audited in June and July was randomly chosen, China’s Ministry of Finance said Tuesday. Also included were China’s biggest domestic drug firms, among them Jiangsu Hengrui Medicine Co. and Shanghai Fosun Pharmaceutical Group Co. The announcement sent an index of health-care companies traded in Shanghai and Shenzhen down 1.8%. Shandong Buchang Pharmaceuticals Co., whose chairman Zhao Tao was recently in the news for allegedly paying a $6.5 million bribe to get his daughter into Stanford University, was also on the list released Tuesday.
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma News Summary: Isatuximab, an investigational ...